Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Type II transmembrane serine proteases.

Szabo R, Wu Q, Dickson RB, Netzel-Arnett S, Antalis TM, Bugge TH.

Thromb Haemost. 2003 Aug;90(2):185-93. Review.

PMID:
12888865
2.

Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix.

Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ.

Cell. 2003 Jul 11;114(1):33-45.

3.

Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.

Almholt K, Nielsen BS, Frandsen TL, Brünner N, Danø K, Johnsen M.

Oncogene. 2003 Jul 10;22(28):4389-97.

PMID:
12853975
4.

Human and mouse proteases: a comparative genomic approach.

Puente XS, Sánchez LM, Overall CM, López-Otín C.

Nat Rev Genet. 2003 Jul;4(7):544-58. Review.

PMID:
12838346
5.

Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer.

Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, Antalis TM.

Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):237-58. Review.

PMID:
12784999
6.

Role of plasminogen activator-plasmin system in tumor angiogenesis.

Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM, Noël A.

Cell Mol Life Sci. 2003 Mar;60(3):463-73. Review.

PMID:
12737307
7.

Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs).

Becherer JD, Blobel CP.

Curr Top Dev Biol. 2003;54:101-23. Review. No abstract available.

PMID:
12696747
8.

Membrane type-matrix metalloproteinases (MT-MMP).

Zucker S, Pei D, Cao J, Lopez-Otin C.

Curr Top Dev Biol. 2003;54:1-74. Review. No abstract available.

PMID:
12696745
9.

Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells.

Bhatt AS, Takeuchi T, Ylstra B, Ginzinger D, Albertson D, Shuman MA, Craik CS.

Biol Chem. 2003 Feb;384(2):257-66.

PMID:
12675519
10.

Regulation of membrane-type 1 matrix metalloproteinase activity by vacuolar H+-ATPases.

Maquoi E, Peyrollier K, Noël A, Foidart JM, Frankenne F.

Biochem J. 2003 Jul 1;373(Pt 1):19-24.

11.

Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.

Rakic JM, Lambert V, Munaut C, Bajou K, Peyrollier K, Alvarez-Gonzalez ML, Carmeliet P, Foidart JM, Noël A.

Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1732-9.

PMID:
12657615
12.

Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis.

Aimes RT, Zijlstra A, Hooper JD, Ogbourne SM, Sit ML, Fuchs S, Gotley DC, Quigley JP, Antalis TM.

Thromb Haemost. 2003 Mar;89(3):561-72.

PMID:
12624642
13.

Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.

Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ.

J Cell Biol. 2003 Mar 3;160(5):781-91.

15.

Deregulated activation of matriptase in breast cancer cells.

Benaud CM, Oberst M, Dickson RB, Lin CY.

Clin Exp Metastasis. 2002;19(7):639-49.

PMID:
12498394
16.

Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages.

Curino A, Mitola DJ, Aaronson H, McMahon GA, Raja K, Keegan AD, Lawrence DA, Bugge TH.

Oncogene. 2002 Dec 12;21(57):8830-42.

17.

uPAR: a versatile signalling orchestrator.

Blasi F, Carmeliet P.

Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43. Review.

PMID:
12461559
18.
19.

Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma.

Bogenrieder T, Herlyn M.

Crit Rev Oncol Hematol. 2002 Oct;44(1):1-15. Review.

PMID:
12398996
20.

Strategies for MMP inhibition in cancer: innovations for the post-trial era.

Overall CM, López-Otín C.

Nat Rev Cancer. 2002 Sep;2(9):657-72. Review.

PMID:
12209155

Supplemental Content

Support Center